/Investors

WRF Capital

Foundation

Seattle · Pre-Seed–Series B · 22 people tracked

Find your way into WRF Capital

627 people in our graph share verified history with the WRF Capital team — schools, employers, funds. One of them is your warm intro.

Maneeshika Madduriunlockedknows Clarisse Benson · together at WRF Capital (overlapped)
×2knows the team · via WRF Capital
×8knows the team · via Wellcome Trust
knows the team · via Clark University
✨ Fox Verdict
Sign up to see your fit

Investment thesis

WRF Capital invests roughly $5 million annually in Washington-based startups, focusing on spinouts from state nonprofit research institutions such as UW, WSU, Fred Hutch and ISB. It backs pre-seed through Series A companies across life sciences and enabling technologies, with initial checks of $100,000 to $2 million and reserves for follow-ons. Often the first money in, the firm partners with angels and VCs across rounds and can lead investments, syndicating with value-adding firms. It emphasizes rigorous due diligence and selective investing to help commercialize new technologies developed in Washington.

Source: firm website, verified Sep 27, 2026.

Stage
Pre-Seed–Series B
Check
$100K – $2M
HQ
Seattle, Washington, US
Leads rounds
Leads
Instruments
Equity · Grants
Founded
1981
Last 12 months
2 investments
AUM
$40M
Tracked investments
18

Team · 22 people

from the firm's website & curated
Lisa Caldwell· Executive Assistant

What they invest in

from 14 of 18 portfolio companies

Biotech ×9Deep Tech ×4AI & Machine Learning ×3Healthtech ×3Medical Devices ×3EdTech ×2New Materials ×2AgTech ×1

HQs:United States×15

Investments · 18 tracked

founders shown can be your intro path

By year:2026 · 22024 · 22021 · 12019 · 12018 · 12017 · 22015 · 110 dated

2Morrow2morrowinc.cominApr 2021 · $1.5M

2Morrow provides evidence-based digital wellness programs delivered through a smartphone and web app, using Acceptance and Commitment Therapy principles to help people quit tobacco, manage stress, and change health behaviors.

Digital HealthMental HealthWellness & FitnessKirkland, US

Jo Masterson(Executive Officer, Director)inBrandon Masterson(Executive Officer)in

BoardJohn Koster(Director)Eric Larsen(Director)in

Co-investorsPortland Seed FundAlliance of Angels

Accipiter Biosciencesaccipiterbio.cominJul 2026

Accipiter Biosciences uses computational protein design to develop de novo, single-agent protein therapies that engage multiple cell-surface receptors at once, functioning as agonists.

AI & Machine LearningBiotechDeep TechSeattle, US

Matthew Bick(Executive Officer, Director, Promoter)inJavier Castellanos(Executive Officer, Director, Promoter)inHector De Jesus Rincon Arano(Executive Officer, Promoter)Heather Redman(Director)Randall Schatzman(Director)William Canestaro(Executive Officer)in

Co-investorsCreative Destruction Lab (CDL)Flying Fish VenturesArgonautic VenturesColumbus Venture PartnersPack Ventures

AnswerDashanswerdash.cominAug 2015

Seattle, US

JACOB O. WOBBROCK(Executive Officer)inWILLIAM T. COLLERAN(Executive Officer, Director)ANDREW KO(Executive Officer)

BoardWILLIAM MCALEER(Director)inMARK UPSON(Director)MICHAEL FRIDGEN(Director)

Co-investorsCowles VenturesThe W FundVoyager Capital

Arzedaarzeda.comin𝕏Jul 2017 · $12M

Arzeda designs proteins and metabolic pathways using computational tools, including its Archytas protein design software and Scylax metabolic pathway design software.

AI & Machine LearningBiotechDeep TechFoodTechNew MaterialsSeattle, US

Alexandre Zanghellini(Co-Founder & Chief Executive Officer)inEric Althoff(Executive Officer, Director, Promoter)inDavid Baker(Co-founder and Scientific Advisor)Bill Baum(Director)inAndrew Ban(Executive Officer)Daniela Grabs(Executive Officer)

Co-investorsCirculate CapitalFall Line CapitalSofinnova PartnersSustainable Conversion VenturesContinental Grain CompanyLewis & Clark AgriFood+2 more

Bellwether BioinApr 2018

BiotechSeattle, US

Rahul Shendure(Executive Officer, Director, Promoter)inMatthew Snyder(Director)

Co-investorsThe W Fund

BirchAIbirch.aiin

Automates complex call center operations; acquired by Sagility Health.

Co-investorsAllen Institute for AI (AI2) IncubatorFlare Capital PartnersAI GrantRadical Ventures

dopl technologiesdopltechnologies.comin𝕏Jul 2026

Dopl develops a software platform that enables specialists to remotely operate medical devices, beginning with telerobotic ultrasound to deliver diagnostic care to underserved communities.

AI & Machine LearningHealthtechMedical DevicesRoboticsBothell, US

MonskySeslar

Co-investorsSpringTide Ventures100Km Ventures LlcMeasuredTechstarsHustle FundPrecursor Ventures+1 more

Fred Hutchfredhutch.orgin𝕏

Fred Hutch is a cancer research institute that develops biomarkers, therapies, and stem cell products for research and clinical use, and provides data infrastructure and funding to commercialize discoveries into treatments and spinout companies.

BiotechHealthtechMedical DevicesSeattle, US

ISBsystemsbiology.orgin𝕏

The Institute for Systems Biology (ISB) is a research organization focused on systems biology science and education, including curriculum development, educator engagement, and student research programs.

Biotech

Nexgenianexgeniacorp.com

Nexgenia develops proprietary stimuli-responsive polymer-based reagents for molecular and cellular selection, diagnostics, and immunoassays.

BiotechDeep TechNew MaterialsSeattle, US

Ron Myers(Executive Officer, Director)

BoardSteven Gillis(Director)Charles P. Waite(Director)Martin Simonetti(Director)Stewart Parker(Director)David Urdal(Director)

Co-investorsThe W FundAlliance of Angels

Outpace Biooutpacebio.cominAug 2024

Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.

BiotechDeep TechMedical DevicesSeattle, US

Marc Lajoie(Co-founder & Chief Executive Officer)inScott Boyken(Co-founder & Chief Innovation Officer)inStanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)inCharity Scripture(Executive Officer)inEric Soller(Executive Officer)in

Co-investorsArtis VenturesRA CapitalAbstract VenturesATEL VenturesAtinum Investment Co. Ltd.Civilization Ventures Management, Llc+8 more

Pronirasproniras.comFeb 2024

Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.

BiotechHealthtechSeattle, US

CHRISTOPHER TOOMBS(Executive Officer)inLINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)

BoardSTEVEN GILLIS(Director)inThong Le(Executive Officer, Director, Promoter)

Co-investorsACCELERATOR LIFE SCIENCE PARTNERSAlexandriaARCH Venture Partners

Resolve Therapeuticsresolvetherapeutics.com

Biopharma company developing non-immunosuppressive drugs for autoimmune diseases.

James Posada, Ph.D.(Founder)in

Co-investorsNew Science VenturesEaston Capital

UWwashington.eduin𝕏

University of Washington is a public research institution offering undergraduate, graduate, and professional education across multiple campuses and disciplines including engineering, computer science, business, medicine, law, and environmental studies.

EdTechSeattle, US

Co-investorsShumo Chu

WSUwsu.edu

Washington State University is a public research institution operating six campuses across Washington state and online, offering academic programs in fields including health sciences, STEM, business, engineering, and social sciences.

EdTechPullman, US

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

ApoGen BiotechnologiesMDmetrixPhytelligence

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has WRF Capital made?
WRF Capital has 18 tracked investments, including 2 dated in the last 24 months.
What stage does WRF Capital invest at?
WRF Capital invests at the Pre-Seed, Seed, Series A, Series B stages.
What is WRF Capital's typical check size?
WRF Capital typically writes checks of $100K – $2M.
What sectors does WRF Capital focus on?
WRF Capital focuses on AI & Machine Learning, Biotech, Consumer, Data & Infrastructure, Deep Tech, Digital Health, Enterprise Software, Hardware, Healthtech, Medical Devices, New Materials, SaaS.
Where is WRF Capital located?
WRF Capital is headquartered in Seattle, US.
Does WRF Capital lead rounds?
Yes, WRF Capital leads investment rounds.

Co-investors · 1

Ambit Health Ventures

Early-stage venture capital firm focused on digital health innovations including digital diagnostics, digital therapeutics, and tech-enabled services. Based in Boston and Philadelphia with deep clinical expertise and experience building and scaling healthcare ventures.

Firms observed investing alongside WRF Capital, from public investor directories. Shared companies are the overlap with WRF Capital's recorded portfolio.

Similar investors

Featured in lists